上海市广发律师事务所 本法律意见书仅供本次股东大会之目的使用，不得被任何人用于其他任何目 的。本所同意，公司可以将本法律意见书作为公司本次股东大会公告材料，随其 1 兄弟科技股份有限公司（以下简称"公司"）2025 年第一次临时股东大会 于 2025 年 9 月 5 日在浙江省海宁市海洲街道学林街 1 号兄弟科技股份有限公司 会议室召开。上海市广发律师事务所经公司聘请，委派邵彬律师、李文婷律师出 席现场会议。根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上 市公司股东会规则》（以下简称"《股东会规则》"）等法律法规、其他规范性 文件以及《兄弟科技股份有限公司章程》（以下简称"《公司章程》"）的规定， 就本次股东大会的召集和召开程序、召集人及出席会议人员的资格、会议议案、 表决方式和表决程序、表决结果和会议决议等出具本法律意见书。 为出具本法律意见书，本所律师对本次股东大会所涉及的有关事项进行了审 查，查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 公司已向本所保证和承诺，公司向本所律师所提供的文件和所作的陈述和说 明是完整的、真实的和有效的，有关原件及其上面的签字和印章是真实的，且一 切 ...

Core Viewpoint - Brother Technology Co., Ltd. plans to raise up to 436.75 million yuan through a private placement of A-shares to fund the construction of a 600-ton iodinated contrast agent raw material project, expanding its production capacity from 100 tons to 700 tons [1][4]. Group 1: Fundraising and Project Details - The total amount to be raised is capped at 436.75 million yuan, which will be used specifically for the construction of the 600-ton iodinated contrast agent raw material project [1][4]. - The project aims to increase the production capacity of iodinated contrast agent raw materials significantly, enhancing the company's market position [1][4]. Group 2: Risks and Challenges - The project faces multiple risks, including the potential inability to absorb the new production capacity if market demand does not meet expectations or if sales channels are not effectively expanded [2][3]. - The company has experienced significant revenue and profit fluctuations, with a reported loss in 2023 due to declining product prices, which raises concerns about future performance [2][3]. - The fine chemical industry is subject to cyclical fluctuations, and the company’s products are influenced by various factors that can lead to price volatility and impact profit margins [3][4]. Group 3: Issuance and Regulatory Information - The issuance will involve no more than 35 specific investors, with the share price set at no less than 80% of the average trading price over the previous 20 trading days [4]. - The total number of shares issued will not exceed 30% of the company's total share capital prior to the issuance, amounting to a maximum of 31.91 million shares [4].

Group 1 - The company has received approval from the China Securities Regulatory Commission for the issuance of shares to specific targets, as indicated in the announcement dated June 10, 2025 [1][2] - Following the release of the 2025 semi-annual report on August 29, 2025, the company updated the financial data and other changes in the prospectus and related application documents [1] - The board of directors will handle the issuance of shares within the stipulated timeframe and will fulfill information disclosure obligations based on progress [2]

股票代码：002562 股票简称：兄弟科技 公告编号：2025-053 兄弟科技股份有限公司 董事会 2025年9月2日 1 鉴于公司于2025年8月29日披露了《2025年半年度报告》，根据《监管规则适用指引—— 发行类第7号》等相关要求，公司会同相关中介机构对募集说明书等申请文件中涉及的财务数 据及其他变动事项进行了同步更新，具体内容详见公司同日在巨潮资讯网披露的相关公告文 件。 公司董事会将根据上述文件和相关法律、法规的要求及公司股东大会的授权，在规定期 限内办理本次向特定对象发行股票事宜，并根据进展情况及时履行信息披露义务。敬请广大 投资者注意投资风险。 特此公告。 兄弟科技股份有限公司 关于向特定对象发行股票的募集说明书（注册稿）等 申请文件更新的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 兄弟科技股份有限公司（以下简称"公司"）向特定对象发行股票的申请已于2025年6月 收到中国证券监督管理委员会出具的《关于同意兄弟科技股份有限公司向特定对象发行股票 注册的批复》（证监许可〔2025〕1174号），具体内容详见公司于2025年6月1 ...

兄弟科技股份有限公司 （住所：浙江省海宁市周王庙镇联民村蔡家石桥 3 号） 2023 年度向特定对象发行 A 股股票 募集说明书 （注册稿） 保荐机构（主承销商） （住所：中国（上海）自由贸易试验区商城路 618 号） 二〇二五年九月 股票简称：兄弟科技 股票代码：002562 兄弟科技股份有限公司 2023 年度向特定对象发行 A 股股票募集说明书 声 明 本公司全体董事、监事、高级管理人员承诺募集说明书及其他信息披露资 料不存在任何虚假、误导性陈述或重大遗漏，并保证所披露信息的真实、准 确、完整。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保 证募集说明书中财务会计报告真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与 之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由 发行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担证券依法发行后因发行人经营与收 ...

国泰海通证券股份有限公司 关于 兄弟科技股份有限公司 2023年度向特定对象发行A股股票 之 发行保荐书 保荐人（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 二〇二五年九月 发行保荐书 国泰海通证券股份有限公司 关于兄弟科技股份有限公司 2023 年度向特定对象发行 A 股股票之发行保荐书 深圳证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"或"本保 荐人"）接受兄弟科技股份有限公司（以下简称"兄弟科技"、"公司"或"发行 人"）的委托，担任兄弟科技本次向特定对象发行 A 股股票的保荐人。国泰海通 及其保荐代表人根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司证券发行注册管理 办法》（以下简称"《注册管理办法》"）、《证券发行上市保荐业务管理办法》（以 下简称"《保荐管理办法》"）等法律法规和中国证券监督管理委员会（以下简称 "中国证监会"）、深圳证券交易所（以下简称"深交所"）的有关规定，诚实守 信，勤勉尽责，严格按照依法制订的业务规则、行业执业规范和道德准则出具 本发行保荐书，并保证本发行保荐 ...

Core Viewpoint - The company, Brother Technology, has shown positive financial performance in the first half of 2025, with significant growth in net profit and a focus on optimizing production costs and expanding product applications in various industries [6]. Financial Performance - In the first half of 2025, the company reported a main revenue of 1.811 billion yuan, an increase of 3.45% year-on-year [6]. - The net profit attributable to shareholders reached 64.541 million yuan, a substantial increase of 357.17% year-on-year [6]. - The net profit after deducting non-recurring items was 62.531 million yuan, up 463.49% year-on-year [6]. - In Q2 2025, the company recorded a single-quarter main revenue of 892 million yuan, a decrease of 4.16% year-on-year [6]. - The single-quarter net profit attributable to shareholders was 43.6329 million yuan, an increase of 10.96% year-on-year [6]. - The single-quarter net profit after deducting non-recurring items was 43.8077 million yuan, up 18.74% year-on-year [6]. - The company's debt ratio stood at 46.73%, with investment income of -85,800 yuan and financial expenses of 27.1813 million yuan [6]. - The overall gross margin was 18.42% [6]. Product Development and Market Strategy - The company is continuously optimizing production processes and releasing project capacities, particularly in iodine contrast agents and phenol products [2]. - The order method for vitamin products primarily consists of quarterly and monthly orders, with prices based on market conditions [3]. - The company has successfully introduced para-phenol into the PEEK field, completing sample submissions to major domestic PEEK manufacturers, with some clients already validating the product [4]. - The company has a production capacity of 20,000 tons for both ortho-phenol and para-phenol, with applications in various industries including food, daily chemicals, pesticides, pharmaceuticals, dyes, and high polymer materials [5]. - The largest application area currently is in acrylic acid inhibitors, while the PEEK field shows the most growth potential in the future [5]. Industry Context - The iodine contrast agent sector is currently facing challenges due to high raw material prices, centralized procurement policies, and industry competition, but the company's gross margin for these products is expected to improve as market access conditions are met and production capacity is released [6].

Core Viewpoint - The company has successfully entered the PEEK field with its produced para-cresol and is actively promoting its products in this sector [1] Group 1 - The company has completed the sample submission process to major domestic PEEK manufacturers [1] - Some customers have already validated the company's para-cresol products [1] - The company plans to continue promoting and selling para-cresol products in the PEEK field [1]

Core Viewpoint - The company has successfully entered the PEEK field with its produced para-cresol, seizing the opportunity for domestic substitution by 2025 [1] Group 1 - The company has completed sample submissions to major domestic PEEK manufacturers [1] - Some clients have already passed the verification process for the company's para-cresol products [1] - The company will continue to promote and sell para-cresol products in the PEEK sector [1]

Group 1 - The company has a production capacity of 20,000 tons for both ortho-phenylphenol and para-phenylphenol [1] - The downstream applications of para-phenylphenol span various industries including food, daily chemicals, pesticides, pharmaceuticals, dyes, and high polymer materials [1] - The largest current application field is as an acrylic acid polymerization inhibitor, while the area with the greatest growth potential in the future is in PEEK applications [1]